Checkpoint Therapeutics, Inc

(NASDAQ:CKPT)

Latest On Checkpoint Therapeutics, Inc (CKPT):

Date/Time Type Description Signal Details
2023-05-24 00:53 ESTNewsCheckpoint Therapeutics prices $10M registered direct offeringN/A
2023-05-15 22:12 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.89N/A
2023-04-05 04:47 ESTNewsCheckpoint: Lesson On How To Destroy Shareholder Value With Serial, Small Financings Despite Good P3 Data And Pending PDUFA DateN/A
2023-03-31 18:38 ESTNewsCheckpoint Therapeutics GAAP EPS of -$7.09 misses by $2.36N/A
2023-03-31 18:38 ESTNewsCheckpoint Therapeutics to raise $6.1M in stock offeringN/A
2023-03-25 00:19 ESTNewsCheckpoint Therapeutics files for $150M mixed shelf offeringN/A
2023-03-02 14:40 ESTNewsCheckpoint's antibody therapy for skin cancer gets FDA reviewN/A
2023-02-21 09:19 ESTNewsCheckpoint Therapeutics stock dips on ~$7.5M securities offeringN/A
2023-01-10 21:00 ESTNewsCheckpoint Therapeutics: An Updated AnalysisN/A
2022-12-16 01:30 ESTNewsCheckpoint Therapeutics announces $7.5M direct offeringN/A
2022-12-05 23:33 ESTNewsCheckpoint Therapeutics falls 8.6% on 1-for-10 reverse stock splitN/A
2022-11-09 03:52 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.12 beats by $0.03, revenue of $0.05MN/A
2022-10-05 04:52 ESTNewsAstraZeneca – LogicBio deal indicates more such takeovers are ahead – CantorN/A
2022-09-08 09:07 ESTNewsCheckpoint: Strong Data, But Comes With RisksN/A
2022-08-12 16:52 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01MN/A
2022-06-16 16:45 ESTNewsCheckpoint Therapeutics trial generates positive interim results for skin cancer candidateN/A
2022-05-14 13:35 ESTNewsCheckpoint gains as H.C. Wainwright cheers key regulatory milestone in EuropeN/A
2022-05-13 08:45 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.20N/A
2022-04-19 04:11 ESTNewsCheckpoint Therapeutics: Potential Upside Based On Marketing Application SubmissionsN/A
2022-03-28 17:53 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.75 misses by $0.24, revenue of $0.27M misses by $0.09MN/A
2022-01-28 22:15 ESTNewsCheckpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline ResultsN/A
2022-01-26 03:24 ESTNewsCheckpoint Therapeutics jumps after trial win; Analysts boost price targetN/A
2022-01-25 10:34 ESTNewsCheckpoint reports positive results from registration trial of cosibelimab in skin cancerN/A
2021-11-26 14:13 ESTNewsCheckpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data ReadoutN/A
2021-10-02 08:21 ESTNewsCheckpoint Therapeutics (CKPT) Investor Presentation - SlideshowN/A
2021-08-06 00:08 ESTNewsCheckpoint Therapeutics EPS misses by $0.02, beats on revenueN/A
2021-07-21 00:45 ESTNewsBiogen’s risks fueling drug pricing debate Citi says, AstraZeneca remains top pick at BofA: in today's analyst actionN/A
2021-07-21 00:44 ESTNewsCheckpoint surges 24% on B. Riley buy initiation, 567% upside potentialN/A
2021-07-21 00:10 ESTNewsCheckpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab DataN/A
2021-05-07 05:42 ESTNewsCheckpoint Therapeutics EPS beats by $0.01, misses on revenueN/A
2021-03-11 07:23 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 03:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $17.67 to $15.25.Neutral
2021-03-10 15:19 ESTEarnings EstimateAn EPS average of -$0.23 is estimated for the 2022 year.Sell
2021-03-10 15:19 ESTEarnings EstimateAn EPS average of -$0.08 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-10 09:23 ESTNewsCheckpoint Therapeutics EPS misses by $0.09, misses on revenueN/A
2021-03-02 09:56 ESTNewsCheckpoint Therapeutics forms a scientific advisory boardN/A
2021-02-17 01:12 ESTNewsChecking In On Checkpoint TherapeuticsN/A
2021-01-20 15:54 ESTNewsCheckpoint Therapeutics initiated at Cantor with OverweightN/A
2021-01-20 11:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $18.5 to $17.67.Neutral
2020-12-30 11:24 ESTAnalyst RatingThe Analyst Target Price has increased from $15 to $18.5.Buy
2020-12-18 09:17 ESTNewsCheckpoint Therapeutics launches $100M ATM equity offeringN/A
2020-12-13 03:33 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 23:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 15:24 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 19:23 ESTEarnings EstimateAn EPS average of -$0.08 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-06 07:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-05 01:15 ESTNewsCheckpoint Therapeutics EPS misses by $0.01, misses on revenueN/A
2020-11-02 21:15 ESTNewsCheckpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung BiologicsN/A
2020-11-01 17:32 ESTFinancialsCompany financials have been released.Neutral
2020-09-30 08:28 ESTAnalyst RatingThe Analyst Target Price has increased from $14.33 to $15.Buy

About Checkpoint Therapeutics, Inc (CKPT):

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Quotes by TradingView

See Advanced Chart

General

  • Name Checkpoint Therapeutics, Inc
  • Symbol CKPT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Fiscal Year EndDecember
  • IPO Date2017-06-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.checkpointtx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 179.66
  • Price/Book (Most Recent Quarter) 7.31
  • Enterprise Value Revenue 203.89
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.53
  • Next Year EPS Estimate -$0.62
  • Operating Margin -2170%
  • Return on Assets -42%
  • Return on Equity -85%
  • Revenue 1.07 million
  • Earnings Per Share -$1.01
  • Revenue Per Share $0.02
  • Gross Profit -15283000
  • Quarterly Earnings Growth 8%
View More

Highlights

  • Market Capitalization 249.71 million
  • PE Ratio -2.45
  • Analyst Target Price $15.25
  • Book Value Per Share $0.51
View More

Share Statistics

  • Shares Outstanding 68.21 million
  • Shares Float 59.96 million
  • % Held by Insiders 1262%
  • % Held by Institutions 21.39%
  • Shares Short 2.17 million
  • Shares Short Prior Month 2.37 million
  • Short Ratio 1.1
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.73
  • 52 Week High $5.38
  • 52 Week Low $1.05
  • 50 Day Moving Average 3.48
  • 200 Day Moving Average 2.9
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Checkpoint Therapeutics, Inc (CKPT) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Checkpoint Therapeutics, Inc (CKPT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$27000-$0.17-$0.08-112.5%
2020-09-302020-11-04$N/A-$0.09-$0.08-12.5%
2020-06-302020-08-05$N/A-$0.09-$0.090%
2020-03-312020-05-06$N/A-$0.06-$0.1352.64%
2019-12-312020-03-11$25000-$0.22-$0.17-31.97%
2019-09-302019-11-07$280000-$0.15-$0.1710.02%
2019-06-302019-08-08$1.05 million-$0.15-$0.164.76%
2019-03-312019-05-09$352000-$0.18-$0.2733.33%
2018-12-312019-03-15$3.03 million-$0.38-$0.30-28.81%
2018-09-302018-11-02$5000-$0.32-$0.23-39.13%
2018-06-302018-08-07$127000-$0.23-$0.3432.35%
2018-03-312018-05-10$343000-$0.35-$0.20-75%
2017-12-312018-03-15$332000-$0.26-$0.3114.75%
2017-09-302017-11-03$349000-$0.26-$0.3321.21%
2017-06-302017-08-09$351000-$0.28-$0.26-7.69%
2017-03-312017-05-10$693000-$0.20-$0.2520%
2016-12-312017-03-17$498000-$0.34-$0.25-36.28%

Checkpoint Therapeutics, Inc (CKPT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Checkpoint Therapeutics, Inc (CKPT) Chart:

Checkpoint Therapeutics, Inc (CKPT) News:

Below you will find a list of latest news for Checkpoint Therapeutics, Inc (CKPT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Checkpoint Therapeutics, Inc (CKPT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-03-212.50CALL0 0485.93TRUE00
2025-03-2150.2CALL40 1112178.51FALSE0.050.33
2025-03-217.50.1CALL0 915832.28FALSE00
2025-03-212.50.2PUT1 10147.66FALSE0.20
2025-03-2150PUT0 0268.5TRUE00
2025-03-217.50PUT0 0236.41TRUE00
2025-04-172.51.05CALL100 1417147.97TRUE-0.02-0.02
2025-04-1750.3CALL103 5244151.3FALSE00
2025-04-177.50.05CALL0 500153.36FALSE00
2025-04-172.50.3PUT0 1386146.91FALSE00
2025-04-1751.95PUT0 294225.88TRUE00
2025-04-177.54.4PUT0 7174.47TRUE00
2025-07-182.51.3CALL110 970128.79TRUE-0.1-0.07
2025-07-1850.65CALL1 733136.83FALSE0.030.05
2025-07-187.50.45CALL0 403132.63FALSE00
2025-07-182.50.6PUT20 518132.08FALSE-0.05-0.08
2025-07-1852.3PUT0 250232.73TRUE00
2025-07-187.54.49PUT0 1254.49TRUE00
2025-10-172.50CALL0 0276.27TRUE00
2025-10-1750CALL0 0326FALSE00
2025-10-177.50CALL0 0350.79FALSE00
2025-10-172.50PUT0 0681.24FALSE00
2025-10-1750PUT0 0130.29TRUE00
2025-10-177.50PUT0 0145.31TRUE00

Latest CKPT Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST16$1.075
Jun 13, 2022 7:59 PM EST4$1.075
Jun 13, 2022 7:59 PM EST100$1.075
Jun 13, 2022 7:59 PM EST75$1.075
Jun 13, 2022 7:59 PM EST9$1.075

Checkpoint Therapeutics, Inc (CKPT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071416/0001104659-20-071416-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1651407/000083423719000377/0000834237-19-000377-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465919061166/0001104659-19-061166-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465919061825/0001104659-19-061825-index.htm
2019-11-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465919065521/0001104659-19-065521-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465919065901/0001104659-19-065901-index.htm
2019-11-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465919066058/0001104659-19-066058-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465919066411/0001104659-19-066411-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920024924/0001104659-20-024924-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920024925/0001104659-20-024925-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920031949/0001104659-20-031949-index.htm
2020-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1651407/000110465920032004/0001104659-20-032004-index.htm
2020-04-14PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920046391/0001104659-20-046391-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920049043/0001104659-20-049043-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920050696/0001104659-20-050696-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1651407/000110465920050699/0001104659-20-050699-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920057496/0001104659-20-057496-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920058103/0001104659-20-058103-index.htm
2020-05-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1651407/000110465920065134/0001104659-20-065134-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920065429/0001104659-20-065429-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920069838/0001104659-20-069838-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071407/0001104659-20-071407-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071409/0001104659-20-071409-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071411/0001104659-20-071411-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071412/0001104659-20-071412-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071414/0001104659-20-071414-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071416/0001104659-20-071416-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920090877/0001104659-20-090877-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920091475/0001104659-20-091475-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920105877/0001104659-20-105877-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920106151/0001104659-20-106151-index.htm
2020-09-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920106159/0001104659-20-106159-index.htm
2020-09-18FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920106177/0001104659-20-106177-index.htm
2020-09-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920107034/0001104659-20-107034-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920107061/0001104659-20-107061-index.htm
2020-09-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920108604/0001104659-20-108604-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920113132/0001104659-20-113132-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920121374/0001104659-20-121374-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920122503/0001104659-20-122503-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419022087/0001144204-19-022087-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1651407/000114420419022091/0001144204-19-022091-index.htm
2019-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419022661/0001144204-19-022661-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419024954/0001144204-19-024954-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000114420419025063/0001144204-19-025063-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419030716/0001144204-19-030716-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031016/0001144204-19-031016-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031017/0001144204-19-031017-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031018/0001144204-19-031018-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031021/0001144204-19-031021-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031022/0001144204-19-031022-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031023/0001144204-19-031023-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419038589/0001144204-19-038589-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000114420419038614/0001144204-19-038614-index.htm
2020-09-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1651407/000153561020000112/0001535610-20-000112-index.htm

Checkpoint Therapeutics, Inc (CKPT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Checkpoint Therapeutics, Inc (CKPT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1262%
Institutional Ownership: 2139%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-06-13Scott BoilenDirectorBuy11,442.00110,112.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031017/0001144204-19-031017-index.htm
2020-06-05BARRY M SALZMANDirectorBuy24,390.00112,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071412/0001104659-20-071412-index.htm
2020-06-05Neil HerskowitzDirectorBuy24,390.00112,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071411/0001104659-20-071411-index.htm
2020-06-05Scott BoilenDirectorBuy24,390.00134,502.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071409/0001104659-20-071409-index.htm
2019-06-13LINDSAY A MD ROSENWALDDirectorBuy11,442.00137,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031021/0001144204-19-031021-index.htm
2019-11-20LINDSAY A MD ROSENWALDDirectorBuy100,000.001.27127,000.00237,890.00https://www.sec.gov/Archives/edgar/data/1651407/000110465919066411/0001104659-19-066411-index.htm
2020-06-05LINDSAY A MD ROSENWALDDirectorBuy24,390.00262,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071416/0001104659-20-071416-index.htm
2020-02-24James F III OlivieroCEO, President and DirectorBuy598,000.002,733,000.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920024924/0001104659-20-024924-index.htm
2020-05-21WILLIAM GARRETT GRAYOfficerSell17,104.002.0034,122.48359,896.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920065429/0001104659-20-065429-index.htm
2020-02-24WILLIAM GARRETT GRAYOfficerBuy157,000.00377,000.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920024925/0001104659-20-024925-index.htm
2019-06-13MICHAEL S WEISSDirectorBuy11,442.0037,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031023/0001144204-19-031023-index.htm
2019-06-13Christian BechonDirectorBuy11,442.0061,442.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031016/0001144204-19-031016-index.htm
2020-06-05MICHAEL S WEISSDirectorBuy24,390.0062,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071414/0001104659-20-071414-index.htm
2020-06-05Christian BechonDirectorBuy24,390.0085,832.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071407/0001104659-20-071407-index.htm
2019-06-13BARRY M SALZMANDirectorBuy11,442.0087,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031022/0001144204-19-031022-index.htm
2019-06-13Neil HerskowitzDirectorBuy11,442.0087,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031018/0001144204-19-031018-index.htm